MiR-29a assists in preventing the activation of human stellate cells and promotes recovery from liver fibrosis in mice

Molecular Therapy

Volumn 24, Issue 10, 2016, Pages 1848-1859

  Matsumoto, Yoshinari ^a,b,c   Itami, Saori ^a   Kuroda, Masahiko ^d   Yoshizato, Katsutoshi ^e   Kawada, Norifumi ^a   Murakami, Yoshiki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Osaka Prefecture University   (Japan)

^c OSAKA UNIVERSITY HOSPITAL   (Japan)

^d TOKYO MEDICAL UNIVERSITY   (Japan)

^e PhoenixBio USA Corporation   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CASPASE 9; GELATINASE A; HYDROXYPROLINE; MESSENGER RNA; MICRORNA 29A; PLATELET DERIVED GROWTH FACTOR C; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA; ATELOCOLLAGEN; CARBON TETRACHLORIDE; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE I, ALPHA 1 CHAIN; LYMPHOKINE; MICRORNA; MIRN29 MICRORNA, HUMAN; PLATELET DERIVED GROWTH FACTOR; PLATELET-DERIVED GROWTH FACTOR C; THIOACETAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFIBROTIC ACTIVITY; ARTICLE; CELL ACTIVATION; CELL VIABILITY; COL1A1 GENE; CONTROLLED STUDY; CONVALESCENCE; DOWN REGULATION; DRUG ACTIVITY; DRUG MECHANISM; ENZYME ACTIVITY; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER FIBROSIS; LIVER PROTECTION; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PDGFC GENE; STELLATE CELL; ANIMAL; CELL LINE; CELL SURVIVAL; CHEMICALLY INDUCED; CHEMISTRY; CYTOLOGY; DISEASE MODEL; GENE THERAPY; GENETICS; HEPATIC STELLATE CELL; LIVER CIRRHOSIS; METABOLISM; PROCEDURES;

ANIMALS; CARBON TETRACHLORIDE; CELL LINE; CELL SURVIVAL; COLLAGEN; COLLAGEN TYPE I; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GENETIC THERAPY; HEPATIC STELLATE CELLS; HUMANS; LIVER CIRRHOSIS; LYMPHOKINES; MICE; MICRORNAS; PLATELET-DERIVED GROWTH FACTOR; THIOACETAMIDE;

EID: 84980332248     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2016.127     Document Type: Article

References (38)

1. Friedman, SL (2008). Mechanisms of hepatic fibrogenesis. Gastroenterology 134: 1655-1669
2. Hernandez-Gea, V and Friedman, SL (2011). Pathogenesis of liver fibrosis. Annu Rev Pathol 6: 425-456
3. Tacke, F and Weiskirchen, R (2012). Update on hepatic stellate cells: pathogenic role in liver fibrosis and novel isolation techniques. Expert Rev Gastroenterol Hepatol 6: 67-80
4. Ikegami, T, Zhang, Y and Matsuzaki, Y (2007). Liver fibrosis: possible involvement of EMT. Cells Tissues Organs 185: 213-221
5. Pellicoro, A, Ramachandran, P, Iredale, JP and Fallowfield, JA (2014). Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol 14: 181-194
6. Schuppan, D and Kim, YO (2013). Evolving therapies for liver fibrosis. J Clin Invest 123: 1887-1901
7. Zamore, PD and Haley, B (2005). Ribo-gnome: the big world of small RNAs. Science 309: 1519-1524
8. Murakami, Y, Toyoda, H, Tanaka, M, Kuroda, M, Harada, Y, Matsuda, F et al. (2011). The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS One 6: e16081
9. Wang, XW, Heegaard, NH and Orum, H (2012). MicroRNAs in liver disease. Gastroenterology 142: 1431-1443
10. Szabo, G and Bala, S (2013). MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol 10: 542-552
11. Mann, J, Chu, DC, Maxwell, A, Oakley, F, Zhu, NL, Tsukamoto, H et al. (2010). MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology 138: 705-14, 714.e1
12. Roderburg, C, Urban, GW, Bettermann, K, Vucur, M, Zimmermann, H, Schmidt, S et al. (2011). Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 53: 209-218
13. Sekiya, Y, Ogawa, T, Yoshizato, K, Ikeda, K and Kawada, N (2011). Suppression of hepatic stellate cell activation by microRNA-29b. Biochem Biophys Res Commun 412: 74-79
14. Bandyopadhyay, S, Friedman, RC, Marquez, RT, Keck, K, Kong, B, Icardi, MS et al. (2011). Hepatitis C virus infection and hepatic stellate cell activation downregulate miR-29: miR-29 overexpression reduces hepatitis C viral abundance in culture. J Infect Dis 203: 1753-1762
15. Janssen, HL, Reesink, HW, Lawitz, EJ, Zeuzem, S, Rodriguez-Torres, M, Patel, K et al. (2013). Treatment of HCV infection by targeting microRNA. N Engl J Med 368: 1685-1694
16. Fitzgerald, K, Frank-Kamenetsky, M, Shulga-Morskaya, S, Liebow, A, Bettencourt, BR, Sutherland, JE et al. (2014). Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 383: 60-68
17. Sun, Y, Xi, D, Ding, W, Wang, F, Zhou, H and Ning, Q (2014). Soluble FGL2, a novel effector molecule of activated hepatic stellate cells, regulates T-cell function in cirrhotic patients with hepatocellular carcinoma. Hepatol Int 8: 567-575
18. Lai, KK, Shang, S, Lohia, N, Booth, GC, Masse, DJ, Fausto, N et al. (2011). Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten null mouse models. PLoS Genet 7: e1002147
19. Kwiecinski, M, Elfimova, N, Noetel, A, Tox, U, Steffen, HM, Hacker, U et al. (2012). Expression of platelet-derived growth factor-C and insulin-like growth factor I in hepatic stellate cells is inhibited by miR-29. Lab Invest 92: 978-987
20. Aouadi, M, Tesz, GJ, Nicoloro, SM, Wang, M, Chouinard, M, Soto, E et al. (2009). Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 458: 1180-1184
21. Lee, JS, Kang Decker, N, Chatterjee, S, Yao, J, Friedman, S and Shah, V (2005). Mechanisms of nitric oxide interplay with Rho GTPase family members in modulation of actin membrane dynamics in pericytes and fibroblasts. Am J Pathol 166: 1861-1870
22. Pescatore, LA, Bonatto, D, Forti, FL, Sadok, A, Kovacic, H and Laurindo, FR (2012). Protein disulfide isomerase is required for platelet-derived growth factor-induced vascular smooth muscle cell migration, Nox1 NADPH oxidase expression, and RhoGTPase activation. J Biol Chem 287: 29290-29300
23. Mehrotra, M, Krane, SM, Walters, K and Pilbeam, C (2004). Differential regulation of platelet-derived growth factor stimulated migration and proliferation in osteoblastic cells. J Cell Biochem 93: 741-752
24. Dumaz, N and Marais, R (2003). Protein kinase A blocks Raf-1 activity by stimulating 14-3-3 binding and blocking Raf-1 interaction with Ras. J Biol Chem 278: 29819-29823
25. Wang, Z, Wang, DZ, Hockemeyer, D, McAnally, J, Nordheim, A and Olson, EN (2004). Myocardin and ternary complex factors compete for SRF to control smooth muscle gene expression. Nature 428: 185-189
26. Feng, XJ, Pan, Q, Wang, SM, Pan, YC, Wang, Q, Zhang, HH et al. (2016). MAP4K4 promotes epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma. Tumour Biol (epub ahead of print)
27. Liu, AW, Cai, J, Zhao, XL, Jiang, TH, He, TF, Fu, HQ et al. (2011). ShRNA-targeted MAP4K4 inhibits hepatocellular carcinoma growth. Clin Cancer Res 17: 710-720
28. Church, LD, Cook, GP and McDermott, MF (2008). Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol 4: 34-42
29. Hemmann, S, Graf, J, Roderfeld, M and Roeb, E (2007). Expression of MMPs and TIMPs in liver fibrosis-A systematic review with special emphasis on anti-fibrotic strategies. J Hepatol 46: 955-975
30. Chua, MS, Sun, H, Cheung, ST, Mason, V, Higgins, J, Ross, DT et al. (2007). Overexpression of NDRG1 is an indicator of poor prognosis in hepatocellular carcinoma. Mod Pathol 20: 76-83
31. Fujimura, K, Bessho, K, Kusumoto, K, Ogawa, Y and Iizuka, T (1995). Experimental studies on bone inducing activity of composites of atelopeptide type I collagen as a carrier for ectopic osteoinduction by rhBMP-2. Biochem Biophys Res Commun 208: 316-322
32. Minakuchi, Y, Takeshita, F, Kosaka, N, Sasaki, H, Yamamoto, Y, Kouno, M et al. (2004). Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res 32: e109
33. Frohlich, E (2012). The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomedicine 7: 5577-5591
34. Iwaisako, K, Haimerl, M, Paik, YH, Taura, K, Kodama, Y, Sirlin, C et al. (2012). Protection from liver fibrosis by a peroxisome proliferator-Activated receptor agonist. Proc Natl Acad Sci USA 109: E1369-E1376
35. Koyama, Y, Taura, K, Hatano, E, Tanabe, K, Yamamoto, G, Nakamura, K et al. (2014). Effects of oral intake of hydrogen water on liver fibrogenesis in mice. Hepatol Res 44: 663-677
36. Takeshita, F, Patrawala, L, Osaki, M, Takahashi, RU, Yamamoto, Y, Kosaka, N et al. (2010). Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 18: 181-187
37. Thuy, le TT, Matsumoto, Y, Thuy, TT, Hai, H, Suoh, M, Urahara, Y et al. (2015). Cytoglobin deficiency promotes liver cancer development from hepatosteatosis through activation of the oxidative stress pathway. Am J Pathol 185: 1045-1060
38. Xu, L, Hui, AY, Albanis, E, Arthur, MJ, O'Byrne, SM, Blaner, WS et al. (2005). Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 54: 142-151